Peralta-Leal Valeria, Durán-González Jorge, Leal-Ugarte Evelia
Centre Universitario, Ciencias de la Salud, Universidad de Guadalajara.
Rev Invest Clin. 2008 May-Jun;60(3):255-62.
Neurogenic diabetes insipidus (NDI) is a rare condition characterized by polyuria and polydipsia caused by deficient arginine vasopressin hormone production. More than a 50 mutations have been identified for familial autosomic dominant neurogenic diabetes insipidus (FadNDI). These mutations can cause citotoxicity and lead to the degeneration of magnocellular neurons of the hipofisis by aberrant protein accumulation. The NDI diagnosis is based on the water deprivation test, quantification of AVP hormone and Magnetic Resonance Image (MRI), and in families with history of FadNDI has been suggested the molecular analysis of mutation in the arginine vasopressin neurophisin II gene before the signs and symptoms development, with the purpose of offering a suitable diagnosis, clinical follow up and treatment. The treatment with a synthetic analogue of AVP hormone allows the remission of the signs and symptoms in NDI patients and the advances in gene therapy in animal models has been promising, as much for NDI as for other diseases in which the mutant protein production has been involved.
神经源性尿崩症(NDI)是一种罕见病症,其特征为因精氨酸加压素分泌不足导致的多尿和烦渴。已确定超过50种与家族性常染色体显性神经源性尿崩症(FadNDI)相关的突变。这些突变可导致细胞毒性,并通过异常蛋白质积累导致垂体大细胞神经元变性。NDI的诊断基于禁水试验、抗利尿激素(AVP)定量和磁共振成像(MRI),对于有FadNDI家族史的患者,建议在体征和症状出现之前对精氨酸加压素神经垂体素II基因进行突变分子分析,以便进行适当的诊断、临床随访和治疗。使用AVP激素的合成类似物进行治疗可使NDI患者的体征和症状得到缓解,动物模型中基因治疗的进展前景良好,对NDI以及其他涉及突变蛋白产生的疾病均是如此。